AGENDA

TIME TOPIC

PLENARY SESSION7:00-8:008:00-8:20

Check in and free networkingOpening Remarks

Xinxin Li, VP of Strategic Partnerships, MyBioGate

8:20-9:20

9:20-10:50

10:50-11:40

11:50-12:30

12:30-13:30

13:30-14:15

14:15-15:00

15:00-15:15

15:15-15:30

15:30-16:15

16:15-17:00

Keynote speechesDiscovering HER2, Herceptin – And Opportunities for Future Breakthroughs through Global-American-Chinese Research Collaboration – 2019 Lasker Award winner; Herceptin inventor, H. Michael ShepardGlobal life science and healthcare investment and finance 2019 – Katherine Andersen, Head of Life Science & Healthcare,

Silicon Valley Bank

Chinese companies’ road to world-class corporationsModerator: Helen Chen – Greater China Managing Partner, L.E.K. ConsultingInternationalization of Chinese companies in Healthcare – Dajian Cai, GTJA Investment GroupPhoenix Reborn--Innovative R&D Strategy and Plan of Gloria Biosciences – Helena Meng, VP and CMO, Gloria BiosciencesRising China Biotech: The CStone Story – Shirley Zhao, CStone PharmaOpportunities and challenges in China healthcare market – Helen Chen, L.E.K. ConsultingFireside chat Dajian Cai – Chairman, GTJA Investment GroupShirley Zhao – Great China General Manager & Head of Commercial, CStone Pharma Austin Zhu – President of Gloria Pharmaceuticals, General Manager of Gloria Biosciences

Introduction of Nanjing Jiangbei New Area Chanmei Chen – Executive Deputy Director of Nanjing Municipal Jiangbei New Area Administrative

Panel 3 – Market needs and access in China (Panel Partner: BioKatalyst)Moderator: Paul Zhang – Partner, Bluestar Bioadvisors LLC; President, BioKatalystPanelists:Bing Yuan – Chief Business Officer, Cstone PharmaceuticalsZhimin Jimmy Zhang – Venture Partner, Lilly Asia VenturesDerek Small - Founding General Manager, Assembly Biosciences Research & Development Co. ShanghaiJonathan Wang – Senior VP Head, Business Development, Zai LabLingyun Dong – General Manager, Yeedozencom Science & Technology

Panel 4 – Chinese pharma’ s overseas outreach and collaborationModerator: Jun Bao – President and CEO, Impact TherapeuticsPanelists: Geffrey Gao – Executive VP/Deputy GM, Harbin Pharmaceutical GroupLarry Cai – Executive Director of BD, Fosun pharmaXiangbin Xu – President, Simcere Innovation CenterBrad Loncar – CEO, Loncar InvestmentsLu Cao - US Head of Corporate Banking for Chinese Multinationals, J.P. Morgan

Medical device elevator pitch ( Company Info on page 9 )

Lunch Break

Break

Panel 2 – China market needs for medical devicesModerator: Tianji Zhu, VP, CD CapitalPanelists:Yonghui Shi – Managing Director, Metronic China FundAdam Zhao – Partner, Anlong FundYu Fang – Partner, 3E Bioventures CapitalDrake Yu – Founding Partner, LYFE Capital

Fireside Chat – MNCs’ strategies to meet new opportunities and challenges in the China marketModerator: Dennis Purcell – Founder and Senior Advisor, Aisling CapitalGuest speakers:Wei Jiang – Executive Vice President and President, Bayer Pharmaceuticals Region China & APAC;President, Bayer Group Greater China

Panel 1 – New landscape and trends of investment in life science & healthcareModerator: Kim Nearing – Venture Partner, BVCF Management, ltd.Panelists:James Huang – Founding Partner, Panacea Venture; Managing Partner, KPCB China Amy Tang – Venture Partner, Qiming Venture PartnersBo Liu – Executive VP & Managing Director- Healthcare Investments, CDIB CapitalJohn Zhu – Partner, 6 Dimensions CapitalMark Tang – Managing Director, Good Health Capital Wendy Pan – Partner, Goodwin LLP

–

Route Exploration of the Drug Marketing Authorization in ChinaModerator: Lingyun Dong – General Manager of Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd.Panelists:Zhen Chen – Chief Scientist & Deputy General Manager of Beijing YEEDOZENCOM Healthcare Science &

Technology Co., Ltd.Xiumin Huo – Professor of YEEHONG Business SchoolZhi Xiao – Managing Director, SDIC FundZhenyu Li – Business Development Director of LUNAN PHARMACEUTICAL GROUP CORP.

TIME TOPIC

11:00—12:00

13:30-14:00

AI and novel therapeutic solutionsModerator: Echo Hindle-Yang – CEO at M.S.Q. VenturesPanelists:Hainian Zeng – CEO, Silexon AI TechnologyAlan Jiang – CSO, XtalPiAndrew Radin – CEO, twoXARGuo-liang Yu – Global CEO, Apollomics IncDaniel Teper – Co-Founder, Chairman & CEO, CYTOVIA Therapeutics

Interpretation of the Latest Pharmaceutical Administration Law of the People's Republic of China and Provisions for Drug Registration.

Zhen Chen – Chief Scientist & Deputy General Manager of Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd.

Q&A for Medicine Launching Regulations in China MarketZhen Chen – Chief Scientist & Deputy General Manager of Beijing YEEDOZENCOM Healthcare Science &

Technology Co., Ltd.

Tea Break

Morning: AI and Digital health

14:00-14:15

15:00-15:30

15:30-16:00

Introduction of YEEDOZENCOMLingyun Dong – General Manager of Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd.

14:15-15:00

Afternoon: Session sponsored by YEEDOZENCOM

AGENDABREAKOUT A

14:30 - 15:40TomoWave LaboratoriesBrainstorm Medical Inc.Fibralign CorporationYolia HealthPacific Diabetes TechnologiesThermopeutiX, Inc.Vave Health, Inc

15:50 - 16:50PhysioCue, Inc.PhotoniCare, Inc.Replication Medical, Inc.Cosm MedicalNanochon, LLC.Eyedetec Medical, Inc.

17:00 - 17:50Abilitech Medical, Inc.Aevumed Inc.TriReme MedicaliHear Medical

TIME TOPIC

10:00-11:00

11:10-11:40

13:30-14:30

14:30-18:00

Technological bottlenecks and breakthroughs in cell and gene therapyModerator: Alain Vertès – Managing Director, NxR Biotechnologies GmbHPanelists:Zhenhua Wu – CEO, Exegenesis BioLynnet Koh – CEO, TargazymeJason Slingby – CBO, Oxford BiomedicaFrank Zhang – CEO, GenScript

Jiangsu Innovative Healthcare Companies Introduction

Projects Partnering

Morning: Cell and Gene therapy

JITRI Southern California Innovation Center Introduction Calvin Chen - CEO of CrossLinkBio,Inc.

11:40-11:50

12:00-13:00

13:00-13:20

Lunch networking with Jiangsu companies and investors

Jiangsu Industrial Technology Research Institute (JITRI) Introduction Paul E. Burrows - Vice President of Jiangsu Industrial Technology Research Institute

Innovation in Jiangsu

Medical device company presentation

AGENDABREAKOUT B

TIME SESSION

10:00-10:05

10:05-12:30

15:15-17:30

Opening Ginger Ding, Director of Investment Analyst, MyBioGate

Gain Insights in Dealmaking by Hearing Real World Case StudiesZhenhua Wu, CEO, Exegenesis BioDavid Poon, Vice President of Business Development, ZymeworksShawn Zhang, VP, AmbrxAnu Balendran, Vice President Business Development, Alligator BioscienceDarrin Crisitello, Chief Commercial Officer, Mission BioJames Lee, Sr. Business Development Manager, Atomwise

Company PresentationTorbjorn Furuseth, CFO, TargovaxLu Wang, Vice President, Flow PharmaBen Bobo, Founder & CEO, CerenetxPing Rawson, Chief Financial Officer, Dyadic InternationalFranz Gruz, CEO, Maintect GmbH Zhijun Zhang, CSO, Zhimeng BiopharmaAnna Sumeray, CEO, VirometixWen Luo, Denovo BiopharmaScott Christensen, CEO, OncoGenesisGeorge Simeon, CEO, Curevo VaccineLucy Lu, CFO, Suzhou Kintor Pharmaceuticals

Company PresentationHuiru (Jane) Wang, CEO, Huirui BiopharmaMichael Tardugno, CEO, CelsionLiming Yang, CEO, Wyze BiotechMark Colbrie, CEO, Strateos

Company PresentationHaijin Meng, Vice President, Chief Medical Officer, Gloria BiosciencesSean Hu, CEO, AvotresPeter Fedichev, CEO, GeroYing Chen, Senior Vice President of Marketing, Bayer PharmaceuticalsJiang Li, CEO, VivaLNKHenry Oconnell, CEO, Canary SpeechPatrick Lopath, Co-founder and COO, TECLens, LLCChris Lai, CEO, METiS Pharmaceuticals Mahmoud Rafea, Chief Scientist, Erythra

Lunch Break12:30-13:30

13:30-14:30

14:30-15:15

COMPANY PRESENTATION

Kintor is a clinical-stage novel drugs developer in China focusing on the proprietary R&D of potential first-in-class and best-in-class drugs for cancers and other AR-related (antrogen receptor) diseases. It had developed five clinical-stage drug candidates. The lead product, Proxalutamide, is a potential best-in-class drug undergoing phase III clinical trials in China and phase II clinical trials in US for mCRPC as well as clinical trials for breast cancer. Kintor’s mission is to become a global leader in the research, development and commercialisation of innovative therapies, focusing on indications with substantial unmet medical needs, in particular in the AR-related field.

Kintor Pharmaceutical Limited: